List of Excipients in Branded Drug SODIUM ACETATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hospira Inc	SODIUM ACETATE	sodium acetate	0409-3299	ACETIC ACID
Hospira Inc	SODIUM ACETATE	sodium acetate	0409-3299	WATER
Hospira Inc	SODIUM ACETATE	sodium acetate	0409-7299	ACETIC ACID
Hospira Inc	SODIUM ACETATE	sodium acetate	0409-7299	WATER

Generic Drugs Containing SODIUM ACETATE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	sodium acetate	0641-6261	ACETIC ACID
Hikma Pharmaceuticals USA Inc	sodium acetate	0641-6261	WATER
Hikma Pharmaceuticals USA Inc	sodium acetate	0641-6262	ACETIC ACID
Hikma Pharmaceuticals USA Inc	sodium acetate	0641-6262	WATER
Fresenius Kabi USA LLC	sodium acetate	63323-032	ACETIC ACID
Fresenius Kabi USA LLC	sodium acetate	63323-032	WATER

What are the Most Frequently-Used Excipients in SODIUM ACETATE?

# Of NDCs	Excipient
9	ACETIC ACID
9	WATER

Sodium Acetate Excipient Strategy, Regulatory Position, Patent Risk, and Commercial Opportunities

Last updated: September 25, 2026

Sodium acetate is a low-cost, compendial inorganic-organic salt used as an electrolyte, buffering agent, pH adjuster, and formulation aid. Its commercial value is driven less by molecule-level exclusivity and more by injectable quality, low-endotoxin manufacturing, compatibility data, packaging, supply reliability, and combination-product design.

Sodium acetate has no meaningful composition-of-matter patent barrier. The main opportunities are high-purity parenteral grades, ready-to-use electrolyte products, dialysis and parenteral-nutrition formulations, lyophilized products, and proprietary delivery systems.

What is sodium acetate and how is it used in pharmaceutical products?

Sodium acetate is the sodium salt of acetic acid. It is supplied in anhydrous and trihydrate forms.

Attribute	Anhydrous sodium acetate	Sodium acetate trihydrate
CAS number	127-09-3	6131-90-4
Molecular formula	C2H3NaO2	C2H3NaO2·3H2O
Molecular weight	82.03 g/mol	136.08 g/mol
Primary pharmaceutical role	Electrolyte, buffer, pH control	Electrolyte, buffer, pH control
Sodium content by mass	Approximately 28.0%	Approximately 16.9%
Typical dosage form	Sterile aqueous injection, concentrate, admixture	Sterile aqueous injection, concentrate, admixture

Sodium acetate is metabolized to bicarbonate through acetate metabolism. This makes it useful as an alkalinizing electrolyte when chloride loading is undesirable. Injectable products may be used for sodium replacement, metabolic acidosis management, or as a component of compounded parenteral nutrition, depending on the product label and clinical setting.

As an excipient, sodium acetate can control pH, contribute ionic strength, provide sodium, and stabilize pH-sensitive active ingredients. It is also used in laboratory and manufacturing processes, although pharmaceutical applications require tighter control of impurities, bioburden, endotoxin, particulate matter, and residual solvents.

What pharmaceutical functions does sodium acetate perform?

Buffering and pH adjustment

Sodium acetate forms an acetate buffer with acetic acid. The system is most effective near the acetic-acid pKa, approximately 4.76. It is therefore useful in acidic and mildly acidic formulations.

The buffer can protect active pharmaceutical ingredients from pH-driven degradation. Its suitability depends on the drug substance’s degradation profile, target pH, ionic strength, and compatibility with other excipients.

Sodium acetate is less suitable when a formulation requires a neutral or alkaline buffer with strong capacity near pH 7 to 8. Phosphate, citrate, histidine, tromethamine, or bicarbonate may perform better in those ranges.

Electrolyte replacement

Sodium acetate injection is used as a source of sodium ions. The acetate component can be metabolized to bicarbonate, making the product distinct from sodium chloride-based replacement products.

For a sodium acetate formulation, developers must calculate:

• Sodium concentration in mEq/mL
• Acetate concentration in mEq/mL
• Osmolality
• pH range
• Maximum infusion rate
• Dilution requirements
• Compatibility with calcium, phosphate, bicarbonate, and other electrolytes

Tonicity and ionic-strength control

Sodium acetate can contribute to isotonicity and control ionic strength. It may be useful in ophthalmic, parenteral, and other aqueous formulations where sodium chloride would alter stability or chloride exposure.

Its tonicity contribution must be calculated from the selected hydrate form. Substitution of anhydrous sodium acetate for trihydrate on a mass-for-mass basis can produce a material dosing error.

Stabilization of biologic and peptide formulations

Acetate buffers are used in some biologic, peptide, and protein formulations. Sodium acetate may support pH control where acetate has acceptable effects on aggregation, oxidation, deamidation, adsorption, and container interaction.

The opportunity is formulation-specific. Sodium acetate does not automatically provide a commercial advantage over histidine, citrate, phosphate, or other buffers. The value arises when it improves stability, reduces excipient load, supports a lower-volume presentation, or enables a preferred administration route.

What regulatory status does sodium acetate have?

Sodium acetate has a long-established pharmaceutical use and is recognized in major pharmacopoeial systems, including the United States Pharmacopeia/National Formulary and European Pharmacopoeia frameworks. Pharmaceutical products must comply with the applicable monograph, general chapters, current good manufacturing practice requirements, and product-specific specifications.

FDA status

Sodium acetate may appear in two regulatory roles:

1. As the active ingredient in sodium acetate injection or another electrolyte product.
2. As an inactive ingredient in a finished pharmaceutical product.

The FDA Inactive Ingredient Database is route- and dosage-form-specific. A listing does not create broad approval for every concentration or route. Developers must establish safety and suitability for the proposed formulation, including concentration, route, exposure, and patient population.

A sodium acetate injection product may be regulated as an approved prescription drug. A new product can follow an abbreviated pathway when it meets applicable requirements for pharmaceutical equivalence, bioequivalence or other substitutability standards, labeling, manufacturing, and quality. A materially different formulation, delivery system, or clinical use may require a different FDA pathway.

European and international position

In Europe, sodium acetate is used in medicinal products, infusion solutions, dialysis products, and compounded preparations. Regulatory submissions generally rely on pharmacopoeial quality, established pharmaceutical use, product-specific safety, and route-specific justification.

The principal regulatory burden is usually not proving novelty of sodium acetate. It is demonstrating control of the finished sterile product, container closure, impurities, sterility assurance, endotoxins, particulate matter, extractables and leachables, and stability.

What patents protect sodium acetate products?

Sodium acetate itself is an old, well-known compound. A new composition-of-matter patent is not a realistic source of exclusivity.

The potentially relevant patent categories are product- and formulation-specific:

Patent category	Potential claim scope	Commercial importance
Injectable formulation	Concentration, pH, osmolality, excipient combination	Moderate
Ready-to-use infusion	Bag composition, stability, administration method	Moderate
Dual-chamber system	Separation of incompatible components until use	High where compatibility is difficult
Lyophilized product	Cake structure, reconstitution, stabilizer system	Moderate
Parenteral nutrition mixture	Electrolyte ratios and stability	Moderate
Dialysis formulation	Acetate concentration and fluid composition	Moderate
Manufacturing process	Purification, crystallization, low-endotoxin control	Low to moderate
Container closure	Bag, vial, syringe, or ampoule configuration	Moderate
Method of use	Treatment using acetate-based alkalinization or electrolyte replacement	Usually narrow
Device combination	Infusion device or premixed administration system	Moderate to high

A patent search should focus on claims that combine sodium acetate with a therapeutic active, delivery device, dosage form, or manufacturing process. Searches limited to the chemical name will overstate the practical patent landscape because many relevant claims use broader terms such as “acetate salt,” “alkalinizing agent,” “buffer,” or “electrolyte composition.”

When does sodium acetate lose exclusivity?

Sodium acetate has no meaningful remaining molecule-level exclusivity because it is an established compound with extensive historical use.

Exclusivity can still exist at the product level where a sponsor has:

• A patent covering a proprietary combination
• FDA orphan-drug exclusivity
• Pediatric exclusivity
• New clinical investigation exclusivity
• A formulation patent
• A device or container patent
• A protected manufacturing process

These rights attach to a particular product or use, not to sodium acetate generally. A competitor can usually avoid the relevant barrier by using a different concentration, buffer system, presentation, manufacturing process, or administration method, subject to regulatory requirements.

What is the Orange Book status of sodium acetate?

The Orange Book identifies approved drug products and patent or exclusivity information applicable to listed products. Sodium acetate is not protected by a molecule-level Orange Book patent estate.

For an individual sodium acetate injection or combination product, the Orange Book status depends on whether the product is listed, whether the sponsor submitted patent information, and whether any submitted patents meet FDA listing requirements. Patent listings are product-specific and should not be generalized to all sodium acetate products.

Paragraph IV risk is therefore limited for plain sodium acetate products. A generic applicant is more likely to challenge patents covering:

• A premixed electrolyte formulation
• A combination with another active ingredient
• A proprietary infusion bag
• A specific method of treatment
• A stability-enhancing excipient system
• A delivery device

A plain sodium acetate injection with no meaningful listed patents is more likely to face ordinary ANDA competition than a complex patent challenge.

What formulation strategy creates commercial value?

Target high-value routes and settings

The strongest opportunities are in settings where product quality, convenience, or compatibility matters more than raw material price.

Premixed parenteral products

Ready-to-administer or ready-to-dilute sodium acetate products can reduce pharmacy compounding, preparation errors, and inventory complexity. Commercial differentiation may come from:

• Multiple concentrations
• Small-volume syringes
• Standard infusion bags
• Terminal sterilization where feasible
• Low-sodium or high-sodium presentations
• Clear labeling of sodium and acetate equivalents
• Compatibility with automated compounding systems

Parenteral nutrition

Sodium acetate can replace some sodium chloride in parenteral nutrition where chloride reduction is clinically desirable. A supplier can compete through validated compatibility data with amino acids, dextrose, lipids, calcium, phosphate, magnesium, and trace elements.

The central technical issue is precipitation and stability in complex admixtures. Data packages that support pharmacy compounding and automated systems can be more commercially valuable than a low-cost raw material position.

Dialysis and renal-care products

Acetate-containing dialysis fluids have a long history, although bicarbonate-based systems are important competitors. Opportunities exist in specialized dialysis formulations, concentrated solutions, and systems that separate incompatible components until administration.

Patent value is higher when sodium acetate is part of a protected dialysis system rather than sold as a standalone salt.

Biologic and peptide formulations

A sodium acetate buffer may support liquid or lyophilized biologic products. Developers should screen pH, concentration, ionic strength, protein aggregation, subvisible particles, oxidation, adsorption, and freeze-thaw performance.

A formulation patent can be commercially meaningful if the acetate system improves shelf life or enables a differentiated presentation. The patent must claim a technically defined composition and measurable performance, not merely the presence of sodium acetate.

How strong is the sodium acetate patent estate?

The core chemical patent estate is weak because sodium acetate is an old compound. The formulation estate is fragmented and generally narrow.

Risk or asset	Assessment
Composition-of-matter protection	Very low
Generic substitution risk	High for simple injections
Formulation patent potential	Moderate
Manufacturing patent potential	Low to moderate
Device combination potential	Moderate
Regulatory complexity	Moderate for sterile products
Supply-chain differentiation	Moderate to high
Biosimilar exposure	Not applicable to sodium acetate
Orange Book exclusivity	Product-specific, generally limited
Paragraph IV exposure	Low for plain products; higher for complex combinations

The most defensible commercial position is usually created through a combination of regulatory approval, validated manufacturing, customer-specific compatibility data, reliable supply, and a differentiated presentation.

Which companies and manufacturers compete in the market?

Competition generally divides into four groups:

1. Large injectable-drug companies selling electrolyte and infusion products.
2. Generic manufacturers producing sodium acetate injection.
3. Hospital-compounding and outsourcing pharmacies.
4. Pharmaceutical excipient suppliers selling compendial sodium acetate.

The competitive field is regional and product-specific. Companies compete on sterile manufacturing capacity, shortage resilience, quality history, product availability, packaging, hospital contracts, and formulary placement.

Raw-material suppliers compete on:

• USP/NF or Ph. Eur. compliance
• Anhydrous versus trihydrate control
• Low endotoxin
• Heavy-metal and elemental-impurity limits
• Particle-size distribution
• Global regulatory documentation
• Audit readiness
• Batch-to-batch consistency
• Dual sourcing

For injectable use, a lower price does not offset a weak sterility or supply record. Buyers often value qualified alternate sources because electrolyte shortages can disrupt hospital operations.

What manufacturing and intellectual-property barriers matter?

Sodium acetate can be manufactured by neutralizing acetic acid with a sodium source, followed by concentration and crystallization. The basic chemistry is accessible. The pharmaceutical barriers arise in purification and control.

Critical quality attributes include:

• Assay
• Water content
• Identity
• Acetate and sodium stoichiometry
• pH
• Chloride
• Sulfate
• Heavy metals and elemental impurities
• Residual solvents
• Bioburden
• Bacterial endotoxins
• Particulate matter
• Crystalline form and hydrate state

An injectable-grade producer can create commercial value through a qualified low-endotoxin process, validated sterilization strategy, robust container closure, and documented control of hydrate conversion.

Manufacturing patents are unlikely to block entry broadly. Process know-how, regulatory qualification, and customer validation are more important barriers than exclusionary patent claims.

What generic launch scenarios exist for sodium acetate products?

Scenario 1: Plain injectable sodium acetate

This is the most exposed product. Entry can occur through a conventional abbreviated application if the product meets applicable equivalence and quality requirements. Price competition is likely.

Scenario 2: Premixed or ready-to-use presentation

Competition is more dependent on container technology, stability, filling capacity, and hospital procurement. A sponsor may obtain stronger commercial retention even without broad patent protection.

Scenario 3: Complex electrolyte or nutrition formulation

Entry becomes more difficult because the applicant must reproduce or adequately characterize compatibility, stability, and administration performance. Formulation patents may have greater practical relevance.

Scenario 4: Proprietary device or combination product

The device, packaging, or administration workflow may create meaningful differentiation. Patent and regulatory analysis must cover both the formulation and the device.

What revenue exposure and commercial opportunities exist?

Sodium acetate raw material is unlikely to support high margins because the compound is inexpensive and widely available. Revenue opportunity increases when the product solves a clinical or operational problem.

The most attractive segments are:

Segment	Margin potential	Main value driver
Bulk technical material	Low	Price and volume
Compendial pharmaceutical excipient	Low to moderate	Quality and documentation
Sterile injectable concentrate	Moderate	Manufacturing and regulatory compliance
Ready-to-use infusion	Moderate to high	Convenience and supply reliability
Parenteral-nutrition component	Moderate	Compatibility data and pharmacy adoption
Dialysis formulation	Moderate	System integration
Biologic formulation excipient package	High relative to material cost	Stability and lifecycle protection
Proprietary device combination	High	Workflow and patentable delivery system

Revenue exposure is most sensitive to hospital supply contracts, shortages, manufacturing interruptions, and reimbursement rather than to loss of molecule-level patent rights.

How does sodium acetate compare with competing buffers and electrolytes?

Attribute	Sodium acetate	Sodium chloride	Sodium bicarbonate	Sodium citrate	Phosphate buffer
Provides sodium	Yes	Yes	Yes	Yes	Yes
Provides chloride	No	Yes	No	No	No
Can generate bicarbonate physiologically	Yes	No	Already bicarbonate	No	No
Useful acidic-range buffer	Yes	No	No	Yes	Limited
Strong neutral-range buffer	Limited	No	Yes	Moderate	Yes
Precipitation concerns	Product-specific	Generally low	Significant with calcium	Significant with calcium	Significant with calcium
Main commercial role	Electrolyte and buffer	Electrolyte and tonicity	Alkalinizer	Buffer and chelator	Buffer

Sodium acetate is strongest where a sponsor needs sodium and acetate without chloride. Sodium chloride remains the default low-cost electrolyte. Sodium bicarbonate has a different pH and compatibility profile. Citrate and phosphate may provide stronger buffering in selected pH ranges but introduce their own complexation and precipitation risks.

Key Takeaways

• Sodium acetate is an established compound with no meaningful molecule-level patent exclusivity.
• Its principal pharmaceutical roles are electrolyte replacement, buffering, pH adjustment, and chloride reduction.
• Commercial opportunities are concentrated in sterile injectable products, ready-to-use presentations, parenteral nutrition, dialysis, and biologic formulation systems.
• The strongest defensible positions rely on formulation, device, packaging, manufacturing, and stability claims.
• Plain sodium acetate injections face high generic substitution risk and limited Paragraph IV exposure.
• The FDA Inactive Ingredient Database and pharmacopoeial monographs support regulatory positioning but do not eliminate route- and concentration-specific requirements.
• Low-endotoxin quality, hydrate control, compatibility data, and supply reliability are more important commercial barriers than basic chemical manufacturing.
• Biosimilar risk does not apply because sodium acetate is a small-molecule salt, not a biologic.
• The best margin opportunity is downstream from the raw material, particularly in validated sterile products and differentiated delivery systems.

Frequently Asked Questions About Sodium Acetate Pharmaceutical Commercialization

Is sodium acetate an active pharmaceutical ingredient or an excipient?

It can be either. In sodium acetate injection, it is the active electrolyte ingredient. In other products, it can function as a buffer, pH adjuster, tonicity agent, or formulation aid.

Can sodium acetate support a new pharmaceutical patent?

Sodium acetate itself is unlikely to support a new composition-of-matter patent. A patent may be possible for a defined formulation, delivery system, manufacturing process, or therapeutic use with demonstrated technical advantages.

Does sodium acetate require an ANDA for generic injectable products?

A qualifying generic injectable product may use an ANDA pathway, but the pathway depends on the reference product, formulation, labeling, equivalence requirements, and applicable FDA standards.

Is sodium acetate suitable for biologic drug formulations?

It can be suitable for selected proteins, peptides, and other biologics. Suitability depends on pH, aggregation, degradation, adsorption, ionic strength, and compatibility with the container and administration system.

What is the main commercial risk for sodium acetate suppliers?

The principal risks are commodity pricing, injectable manufacturing compliance, supply interruption, customer qualification requirements, and limited product differentiation. Patent expiry is generally not the primary risk.

References

1. European Directorate for the Quality of Medicines & HealthCare. (2023). European Pharmacopoeia (11th ed.). Council of Europe.

2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

4. United States Pharmacopeial Convention. (2023). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (2024). Current good manufacturing practice requirements for finished pharmaceuticals. Code of Federal Regulations, Title 21, Part 211.

6. U.S. Food and Drug Administration. (2024). Current good manufacturing practice for active pharmaceutical ingredients. Code of Federal Regulations, Title 21, Part 210.

7. U.S. Food and Drug Administration. (2024). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages